We are one of the two products in this comparison, so read it with that in mind. What follows is the distinction we think matters, the questions we would ask a vendor in your position, and the cases where ValGenesis is the better choice. We would rather you reached the right decision than a decision in our favour.
The honest summary: ValGenesis is an established validation lifecycle management platform with a long track record in large regulated manufacturers. GxP Copilot is built around generating the validation package rather than managing the people who write it. Those are different categories of product, and which one fits depends less on features than on where your effort currently goes.
The distinction: managing validation versus producing it
Validation management platforms solve a real problem. They replace paper and uncontrolled documents with workflow, routing, electronic signature and a controlled repository. If your current state is documents in a network folder and signatures in ink, that is a large improvement and it is what this generation of tools was built for.
Historically, these platforms did not change who writes the content: the platform routed, versioned and signed the deliverable, and a person still authored it. That matters, because in a typical validation project most hours go into authoring structured documents that follow predictable patterns.
ValGenesis has been moving on this. Its AI assistant, VAL, was introduced in 2025, and a new generation announced in April 2026 supports protocol and trace generation, gap assessment against policies and regulations, and execution review and anomaly identification, inside governed workflows with human review. At announcement it was opening as a limited pilot, so check what is generally available to you.
GxP Copilot starts from drafting. It classifies the system with deterministic rules, drafts the package (assessments, validation plan, requirements with risk, specifications, IQ, OQ and PQ protocols, summary report) and keeps the traceability live, and qualified people review, edit and approve every part. The useful comparison now is not whether each product uses AI, but how each performs on your own material.
What we do not claim
Three things, stated plainly because the category is full of vendors who imply otherwise.
We do not claim AI replaces validation. It does not. Every deliverable is reviewed and approved by a qualified human, every signature is a person's, and the regulatory accountability is unchanged. What changes is the distribution of effort: drafting moves, review and approval do not.
We do not publish a cycle-time figure. It varies so widely with system category, estate maturity and how quickly your approvers turn work around that any single number would mislead more than it informs. If a vendor quotes you one — including a comparison against us — ask what estate it was measured on.
We do not claim to replace an eQMS. GxP Copilot is a validation system. Your quality management system is a different thing and should stay one.
Where ValGenesis is the better choice
Several situations, and they are not edge cases.
- You have already implemented it and it is working. Replacing a functioning validated platform is a project with real cost and real risk. Dissatisfaction has to be substantial to justify it.
- You are a large enterprise with a mature validation practice and a deliberate preference for scripted testing performed by your own people. If your model is working and your estate is under control, the case for change is weaker.
- Your requirement is primarily workflow and document control rather than authoring effort. If your documents are already drafted efficiently and the pain is routing and signature, a validation management platform addresses the problem you actually have.
- Enterprise-wide deployment across many sites is the priority and a long-established vendor relationship carries weight in your procurement process. That is a legitimate factor.
Where we think we are the better fit
Mid-market pharmaceutical and biotech organisations, typically without a large dedicated validation function, where the constraint is that there are not enough qualified people to author the documents the estate requires. That is the problem we built for.
Also organisations moving genuinely to a risk-based approach under the FDA's Computer Software Assurance guidance, finalised in September 2025 and reissued in February 2026. CSA only reduces effort if testing depth actually follows per-requirement risk and the reasoning is documented. Doing that consistently by hand is difficult, which is why many CSA transitions end up as CSV with different paperwork. AI Risk Assessment is how we make the risk determination explicit and the reasoning part of the record.
And organisations that need the traceability to be live rather than reconstructed. A traceability matrix maintained by hand reports whatever it was last told, and one that has never shown a gap has not been stress-tested. Live RTM keeps it current as requirements, risks and evidence change.
The question to ask any vendor claiming AI
Including us. AI has become a feature claim rather than an architecture, and the distinction is worth testing directly.
Ask the vendor to validate their own AI and show you the documentation. The draft EU GMP Annex 22, published for consultation in July 2025 and not yet in force, is a reasonable basis for the questions even though it is not binding: what is the model approved for and what is it not, what evaluation gates a release, what safeguards sit on its outputs, how is drift monitored, and what happens to the workflow when the AI is unavailable.
Any vendor serious about AI in GxP should be able to answer those with documents, and the established vendors increasingly describe their AI as governed and human-led. Ask to see the evidence behind that. Annex 22 assurance is where we publish our own position, and why human-in-the-loop can't be a footnote is why the human review step has to be enforced by architecture rather than by procedure. the best GxP software for 2026 covers the wider category.
How to run the evaluation
Do not evaluate on a demonstration dataset. Both products will look good on data chosen by the vendor.
Bring one of your own systems — ideally an awkward one, with a user requirements specification that is incomplete in the way real specifications are. Ask each vendor to produce the same deliverable from it. Then compare what came out, how much of it a qualified reviewer would accept, how much rework it needed, and how the traceability behaved when you changed a requirement halfway through.
That last test is the revealing one, because changing a requirement late is normal and it is where document-based approaches quietly fall apart.
book a demo and we will run GxP Copilot against your own URS so you can judge the output rather than a demonstration. If the result does not convince you, that is a useful answer too.
Where to go next
Explore GxP Copilot for AI-native validation, TraceDraft for source-traceable clinical documentation, or book a demo to see either on your own data.
